KBroVet-CA1 is a prescription chicken-liver-flavored chewable tablet containing potassium bromide to treat seizure disorders. In addition to therapy, it can be used in combination with other anti-seizure medications or as the sole anticonvulsant. KBroVet-CA1 differs from KBroVet in two ways: 1) KBroVet-CA1 does not contain the inactive ingredient cyanocobalamin (vitamin B12) and 2) tablets are no longer scored. Patients may transition directly to the new formulation, with no need for any dosing adjustments.
KBroVet-CA1 (potassium bromide chewable
tablets) are indicated for the control of
seizures associated with idiopathic epilepsy
Possible Side Effects
In a retrospective field study of 51 dogs diagnosed with idiopathic epilepsy and receiving only KBr to control seizures associated with idiopathic epilepsy, adverse reactions were documented for the initial 60 days of treatment. Increased appetite, weight gain, vomiting/regurgitation and sedation were the most common clinical abnormalities documented in the 60 day period after start of KBr therapy. Adverse reactions were also documented during the 30 days prior to KBr sample submission. Weight gain, weakness, ataxia, and increased appetite were the most common adverse reactions documented during this time period. Adverse events associated with concurrent use of KBr with other antiepileptic drugs such as phenobarbital have been reported. Neurologic signs were the most common adverse event and included sedation, irritability, restlessness, depression, behavioral changes, ataxia, hind limb paresis, mydriasis, stupor, and coma. The neurologic signs were reported to be reversible.
Drug & Food Interactions
KBroVet-CA1 should not be used in animals with a history of hypersensitivity to bromide.
Dogs receiving KBr should be carefully
monitored when changing diets,
administering chloride-containing IV fluids,
and administering concurrent medications.
Careful monitoring is important in dogs that
have a condition that may cause difficulty
maintaining electrolyte balance. Animals with decreased renal function may
be predisposed to bromide toxicosis.
Some dogs may experience epileptic
episodes that are unresponsive or refractory
to KBr monotherapy and KBr alone may not
be adequate treatment for every dog with
The safe use of KBroVet-CA1 has not been
evaluated in dogs that are intended for
breeding, or that are pregnant or lactating.
The safe use of KBr in neonates and
young animals has not been established.
Reproductive effects of KBr have been
reported in other species. In dogs,
ataxia, diarrhea, hematochezia, excessive
salivation, shivering, skin lesions, stupor
progressing to coma and death have been
reported with a dose of 200 to 500 mg/kg
a day for 4 to 26 weeks.
Please note product may arrive in a Chewy Pharmacy vial, manufacturer packaging is shown for reference.
Also available in an oral solution.
Shop Veterinary Diet Food, Supplements, Dental Care & More
See all items by KBroVet-CA1